Applications
Biopharma
Most drugs either are proteins or work on proteins, yet drug discovery has largely relied on genomic proxies to understand them. deSIPHR reads what a cell is actually doing, not what its DNA suggests it might do. With more than 100x improvement in peptide detection sensitivity over mass spectrometry, deSIPHR discovers low-abundance, clinically relevant peptides from limited patient samples.
Immunopeptidomics
Neuropeptide and signaling peptide sequencing
Biologics and antibody development
Protein degrader characterization
Data for AI biology and drug discovery platforms
Biosecurity
The next generation of biosecurity depends on the ability to detect threats that don’t yet exist in any database. deSIPHR sequences proteins de novo — without prior knowledge of whats in the sample — uncovering novel biomarkers, post-translational modifications, and low-abundance signals that current methods miss entirely.
Unknown protein and biothreat detection
De novo identification of engineered or non-canonical proteins
Functional analysis and biothreat mitigation
Supply chain verification and biosurveillance
Bio-AI
The next generation of AI biology — virtual cell models, foundation models for biology, and AI drug discovery platforms — is bottlenecked not by algorithms but by data. Specifically, the right kind of data: high-resolution, single-cell measurements that capture not just what genes are expressed, but what proteins are actually doing, in real time, under perturbation.
Perturb-seq style studies
Cell state differentiation
Longitudinal proteomics
Virtual cell training data